Skip to main content
Premium Trial:

Request an Annual Quote

Losing Its Luster

Derek Lowe doesn't think RNAi will ever be useful in drug therapies, mainly because "nucleic acid-based therapies are just nightmarish to administer," he says. And he's not the only one. In a post at In the Pipeline, Lowe links to a recent CNBC story that details Leerink Swann's coverage of Alnylam. Analysts at the firm say that RNAi is "a drug development tool that we feel is more suited for research purposes than the development of therapeutics" and that Alynlam will probably never develop a successful drug.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.